Skip to main content

The hormones, plainly

The vocabulary, before the prescribing conversation

If you searched 'progesterone' and got contraception, or 'testosterone' and got men's gym content, that's not your fault — it's what the open web optimises for. This is the perimenopause version, with one focused page for each hormone, plus the synthetic family and the newer non-hormonal options.

How they fit together

One conversation, four hormones, talking to each other

The brain (hypothalamus and pituitary) sends FSH and LH down to the ovaries. The ovaries answer back with estrogen and progesterone, on a monthly rhythm. Testosterone runs alongside, made in the ovaries and adrenals, on its own quieter dial. In perimenopause that loop starts to misfire. This is why one symptom is rarely traceable to one hormone.

The cast

Pick the hormone you came here for

Four names you'll keep hearing. Two do most of the day-to-day work, one gets brushed off as "the men's one", and two more turn up mostly on lab forms. Here's each in plain language — in the order they tend to matter.

If you came here from a search

Progesterone is not the same thing as the progestin in your pill

Most search results for "progesterone" point at hormonal contraception, where the active ingredient is a progestin — a synthetic molecule designed to suppress ovulation. The progesterone discussed in perimenopause and MHT is micronized progesterone, a body-identical form taken in a much lower, cyclical dose, usually at night. Same family, very different drug, very different conversation.

Read the progesterone page

The synthetic family, and the newer drugs

Progestins, Premarin, ethinyl estradiol, tibolone, NK3 antagonists, BHRT

A lot of the older fear about HRT is fear of a specific old combination. A lot of the newer marketing about "bioidentical" hormones is selling you something the regulated version already does, more safely. And a genuinely new option (NK3 receptor antagonists like fezolinetant) is starting to give people who can't take estrogen a real lever for hot flashes for the first time.

Read the synthetics page

If you've had a hormone-sensitive cancer

The conversation is different, but it isn't closed

For a long time the answer to "MHT after a hormone-sensitive cancer?" was a flat no, full stop. The picture is more careful than that now. Decisions are made between you, your oncology team, and a menopause-aware doctor — not by a search engine — and they depend on the specific cancer, the receptor status, your treatment, your symptoms, and what's on the table for quality of life.

  • Local vaginal estrogen is a separate question from systemic MHT. The doses are tiny, the systemic absorption is low, and current guidance from major menopause societies treats it as discussable for many people after breast cancer — including those on aromatase inhibitors — when GSM is hurting daily life.
  • Non-hormonal options for hot flashes have moved on. SSRIs and SNRIs (with caveats around tamoxifen interactions), gabapentin, oxybutynin, and the newer NK3 receptor antagonists (fezolinetant, with elinzanetant on the way) give people who can't take systemic estrogen real levers for vasomotor symptoms.
  • Treatment-induced menopause is its own pathway. Chemotherapy, ovarian suppression, oophorectomy, and aromatase inhibitors land harder and faster than the gradual perimenopause story most resources are built around.
  • "No MHT" is a starting position, not the whole answer. Even when systemic MHT is off the table, sleep, mood, joint pain, GSM, libido, bone, and brain symptoms still need a plan.

What this page isn't

A primer, not a prescription

These pages exist so the words make sense before the appointment. They don't tell you what to take, what dose, or which route. The treatments page handles that conversation, and the appointment-prep tools help you take it into the room.